Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci191781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Vera Tiedje und 16 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Thyroid Carcinoma, Anaplastic, Protein Kinase Inhibitors, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH.
Abstract (Originalsprache)
Cancer cells present neoantigens dominantly through MHC class I (MHCI) to drive tumor rejection through cytotoxic CD8 + T cells. There is growing recognition that a subset of tumors express MHC class II (MHCII), causing recognition of antigens by TCRs of CD4 + T cells that contribute to the antitumor response. We found that mouse Braf V600E -driven anaplastic thyroid cancers (ATCs) responded markedly to the RAF plus MEK inhibitors dabrafenib and trametinib (dab/tram) and that this was associated with upregulation of MhcII in cancer cells and increased CD4 + T cell infiltration. A subset of recurrent tumors lost MhcII expression due to silencing of Ciita , the master transcriptional regulator of MhcII , despite preserved IFN-γ signal transduction, which could be rescued by EZH2 inhibition. Orthotopically implanted Ciita –/– and H2-Ab1 –/– ATC cells into immune-competent mice became unresponsive to the MAPK inhibitors. Moreover, depletion of CD4 + , but not CD8 + , T cells also abrogated the response to dab/tram. These findings implicate MHCII-driven CD4 + T cell activation as a key determinant of the response of Braf -mutant ATCs to MAPK inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Oncology and Pathogenesis Program.
- Department of Medicine, and.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, and.
- University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado, USA.
- Antitumor Assessment Core Facility and.
Förderung
- NCI NIH HHS
- NIH
Zitieren
APA
Tiedje, V., Greenberg, J., Qin, T., Im, S. Y., Krishnamoorthy, G. P., Boucai, L., Xu, B., French, J. D., Sherman, E. J., Ho, A. L., de Stanchina, E., Socci, N. D., Jin, J., Ghossein, R. A., Knauf, J. A., Koche, R. P., & Fagin, J. A. (2025). Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers. Journal of Clinical Investigation. https://doi.org/10.1172/jci191781
Vancouver
Tiedje V, Greenberg J, Qin T, Im SY, Krishnamoorthy GP, Boucai L, et al. Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers. Journal of Clinical Investigation. 2025. doi:10.1172/jci191781
BibTeX
@article{Tiedje2025,
author = {Tiedje, Vera and Greenberg, Jillian and Qin, Tianyue and Im, Soo-Yeon and Krishnamoorthy, Gnana P and Boucai, Laura and Xu, Bin and French, Jena D and Sherman, Eric J and Ho, Alan L and de Stanchina, Elisa and Socci, Nicholas D and Jin, Jian and Ghossein, Ronald A and Knauf, Jeffrey A and Koche, Richard P and Fagin, James A},
title = {Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci191781}
}
EUVIMED